β

Psychedelic Research Links May 2023

The research papers on psychedelics that came out in May 2023. Links to chemistry, reviews, case studies on psychedelics.

Published on 5/2/2023

This is all the other psychedelic research that came out in May 2023. These papers don’t (yet) have their own page in our database.

You can find all interesting papers in our Papers Database.

Related Papers

In Rodents

  • Antidepressant effects of repeated s-ketamine administration as NMDAR Antagonist: Involvement of CaMKIIα and mTOR signaling in the hippocampus of CUMS mice (in mice, “It turned out that s-ketamine manifested evident antidepressant effects with improved synaptic plasticity. Meanwhile, the results suggested that s-ketamine could differentially modulate glutamate receptors with upregulated GluN1 and GluR1 levels and downregulated GluN2B levels. CUMS-induced elevation of CaMKIIα phosphorylation and decline of BDNF, TrkB phosphorylation and mTOR could also be reversed through s-ketamine treatment. Together, our study provided evidence that selectively modulated glutamate receptors as well as CaMKIIα and mTOR signaling were involved in repeated s-ketamine administration.“)

Chemistry

  • Ligand and G-protein selectivity in the κ-opioid receptor (“These results provide insights into the actions of opioids and G-protein-coupling specificity at KOR [κ-opioid receptor] and establish a foundation to examine the therapeutic potential of pathway-selective agonists of KOR.”)
  • In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E. coli (production of psychedelics from E. coli, “This work provides a starting point for further genetic and fermentation optimization studies with the goal to increase methylated tryptamine production metrics to industrially competitive levels.”)

Perspectives/Opinions

Reviews

Other

  • Ketamine for depression: a potential role in requests for Medical Aid in Dying? (case study, n=1, “we report the case of a Canadian patient who was actively requesting Medical Assistance in Dying for severe and prolonged treatment-resistant depression until she experienced remarkable benefits from a course of intravenous ketamine infusions. To our knowledge, this is the first report of ketamine or any other intervention yielding remission in a patient who would have otherwise likely been eligible for MAiD for depression. We discuss implications for the evaluation of similar requests and, more specifically, why a trial of ketamine warrants consideration.“)
  • Predictors of Medical Students’ Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice (n=213, medical students, “In this sample, medical students with greater self-assessment of their knowledge about medical psilocybin, less concern for its potential adverse effects, and more positive views about recreational psilocybin legalization predicted positive attitudes about its medical use. Interestingly, although some participants had positive perceptions about the legalization of psilocybin for medical use, endorsing its legalization for recreation was related to greater positive attitudes toward medical psilocybin in general, a finding that appears to be somewhat counterintuitive.“)
Psychedelic Research Links May 2023 - Blossom | Blossom